Introduction
For many years, physicians had few choices for treating epileptic seizures. Within the past 15 years, many ''new generation'' antiepileptic drugs (AEDs) have been introduced. The new agents have been shown in clinical trials to offer similar efficacy compared with older, more established AEDs. 1, 2 Some studies have shown that the new agents offer important improvements in safety and side effect profile. 1, 3 The three ''new generation'' AEDs studied in this audit are lamotrigine, levetiracetam and topiramate, which are the most commonly prescribed ''new generation'' AEDs in the United Kingdom. 4 They were chosen because they are all ''broad spectrum'', in other words they are known to have some effect on the vast majority of seizure types. Most clinical trials of these AEDs initially investigated their efficacy for localisation-related seizures with or without secondary generalisation. [5] [6] [7] [8] [9] [10] There is trial data for lamotrigine and topiramate in primary generalised epilepsy, [11] [12] [13] [14] but as yet the data for levetiracetam is mainly from experience in clinical practice. 15, 16 This means the former two AEDs have wider licences than the latter. Nevertheless, this study reports on usage of all three AEDs in a wide range of seizure types. Seizure (2005) Summary The aim of this audit was to ascertain outcomes for people who had taken or who were still taking three ''new generation'' broad-spectrum antiepileptic drugs (AEDs), namely lamotrigine, levetiracetam and topiramate.
Thirteen percent of people became seizure free and approximately, one-third had a reduction of greater than 50% in their seizures. Two-thirds of people were still taking their audit AED. In addition, approximately one-third of people with a learning disability derived substantial benefit, although the rate of seizure freedom was lower.
All three AEDs were most successful at treating primary generalised epilepsy and least successful with symptomatic generalised epilepsy.
With some reservations the data suggests that levetiracetam and topiramate are the most efficacious AEDs, but topiramate is the least well tolerated. These results mean consideration of a ''general prescribing policy'' is important when using and choosing these AEDs.
We conclude that lamotrigine, levetiracetam and topiramate are useful additions to the armamentarium of AEDs. # 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
The present data available on usage of these three AEDs in everyday adult UK district hospital clinical practice is limited. [16] [17] [18] [19] [20] [21] [22] [23] [24] It is, therefore, important that knowledge is expanded of their usage in a ''general'' epilepsy population, as the results are likely to be different from the trial data. This study aims to contribute to the expansion of this knowledge base.
Methods
Hospital patient notes were searched on three separate occasions for people who were taking or who had taken one of the three audit AEDs. The same search critieria were used on each occasion. In the Results section we, therefore, refer to the number of exposures to the audit AEDs as opposed to the number of people.
The three patient note searches were undertaken approximately 2 years post the United Kingdom licensing of each audit AED. Lamotrigine was, therefore, audited first, topiramate second and levetiracetam third. Some of the cohort had been taking their audit AED much longer than 2 years, because they were initiated on a particular AED pre-licence.
Some people have taken more than one of the audit AEDs and will, therefore, be counted in the data on more than one occasion.
The following categories of information were recorded: audit drug, dose attained on audit drug, name, hospital number, sex, age, age of seizure onset, whether the person had learning disabilities, whether the person had primary generalised, symptomatic generalised or a localisation-related onset epilepsy, outcome for seizure frequency compared to baseline, side effects, whether the person is continuing on the audit AED and if not the length of time before the person stopped taking the audit AED.
Results were recorded in both EXCEL and SPSS 11.0 for Windows. Analysis was completed using SPSS. Where groups of people were compared for significance the statistical test used was chi-square with one exception, for ''time to drop out'' the Kaplan-Meier test was used.
Results

Characteristics of the exposures to an audit AED
Two hundred and ten exposures (45%) were in males and 258 (55%) were in females. Sixty-three (14%) exposures were in those aged 20 years and under, 397 (85%) were 21-65 years old inclusive and 8 (2%) were 66 years and over.
When seizures started, 372 (80%) of the people exposed were aged 20 years and under, 94 (20%) were 21-65 years old inclusive and 0 (0%) were 66 years and over.
Ninety-three exposures (20%) were in people who had primary generalised epilepsy, 57 (12%) had symptomatic generalised epilepsy and 317 (68%) had localisation-related epilepsy.
When audited 245 (52%) were taking lamotrigine (LTG), 94 (20%) were taking topiramate (TPM) and 129 (28%) were taking levetiracetam (LEV).
The following were the doses attained for each of the audit AEDs: Ninety-six exposures (20%) were in people who had learning disabilities.
The following bar chart shows the number of AEDs people were already taking when their audit AED was added (Bar Chart 1).
This second chart shows the number of AEDs the person had already taken at sometime before the introduction of the audit AED (Bar Chart 2).
Cohort characteristics and each drug audited (N = 468)
To try and ascertain whether the exposures to each audit AED were fairly similar, all exposures were compared for their basic characteristics against the drug they were taking at the point of audit.
The groups were similar in the case of age, sex, age of onset, symptomatic generalised epilepsy, An audit of lamotrigine, levetiracetam and topiramate usageChart 1 localisation-related epilepsy and the number with a learning disability.
There was significant difference between each exposure group in that those with primary generalised epilepsy were more likely to be prescribed levetiracetam ( p < .029). There were also significant differences in the number of AEDs exposed people were already taking when the audit AED was added (Bar Chart 1) and the number of AEDs exposed people had already taken at sometime before the introduction of the audit AED (Bar Chart 2).
The latter two pieces of data suggested that the lamotrigine group possibly had less severe epilepsy. For ''AEDTAKE'' the lamotrigine group were taking less other AEDs when it was added than the topiramate group ( p < .001) and the levetiracetam group ( p < .001). This was also the case for ''AEDPRIOR'' where the lamotrigine group had taken less other AEDs before it was introduced: topiramate ( p < .001); levetiracetam ( p < .001). The picture was much less clear when comparing the topiramate and levetiracetam groups. In the case of ''AEDTAKE'' the topiramate group were taking less other AEDs when it was added ( p < .001), but for ''AEDPRIOR'' the levetiracetam group had tried less other AEDs before it was introduced ( p < .040).
Drug efficacy (N = 451) Table 1 outlines the seizure outcome for 451 of the exposures, using commonly agreed markers. Seizure-free is defined as no seizures for 6 months or longer.
People exposures continuing on an audit drug (N = 468) Three hundred and twelve (67%) were continuing on their audit drug and 156 (33%) were not, due to either a lack of efficacy or side effect problems. Time to ''drop-out'' (N = 155) In the case of the exposures where an audit drug had been stopped, Table 2 outlines the length of time it took for this to occur.
Drug efficacy and epilepsy type
Tables 3-5 outline seizure outcome for the three chosen categories.
Levetiracetam efficacy and epilepsy type (N = 126)
For exposures in people who had primary generalised epilepsy six out of 35 (17%) became seizurefree. In the case of localisation-related epilepsy, the figure was eight out of 80 (10%) for those becoming seizure-free and for symptomatic generalised epilepsy, zero out of 12 (0%). Table 6 outlines the efficacy of each audit AED.
Comparison of drug efficacy
Comparison of ''drop-out'' Table 7 outlines how many of the exposures are still taking their audit AED or not.
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Comparison of time to ''drop out'' (N = 155)
The following is a Kaplan-Meier graph comparing the drop-out time of the three audit AEDs.
Exposures in those people with learning disabilities (LDs) Table 8 outlines the seizure outcome using commonly agreed markers. Table 9 outlines the number still taking their audit AED.
Discussion
This is one of the largest cohorts of people with epilepsy taking a new generation antiepileptic reported from a United Kingdom district general hospital. The cohort is not strictly similar to those usually found in neurosciences outpatients as the main consultant has a special interest in epilepsy and is involved with both a joint learning disability clinic and antiepileptic drug trials. This means that the cohort is biased towards the more severe epilepsies in comparison to a standard neurosciences outpatient population. It is probably, therefore, logical to suggest that the outcomes identified may be improved upon in general neurosciences outpatient clinics. The efficacy and usefulness of new generation antiepileptics has been challenged by some 22 and supported by others. 1, 15, 16, 25 This data would suggest a useful role for lamotrigine, topiramate and levetiracetam. Thirteen percent of the exposures to an audit AED led to seizure freedom and 33% led to a greater than 50% decrease. Sixty-seven percent of the exposures were continuing to take their audit drug, which virtually balances with the figure of 69% of the exposures that had some sort of seizure decrease, however, small. If people did stop taking their audit drug, unsurprisingly, they were most likely to do this in the first 6 months (nearly 60% and nearly 90% within 12 months).
This study chose to have a simple regime for classifying epilepsy type: primary generalised, symptomatic generalised and localisation related. The three audit drugs were much more likely to successfully treat primary generalised epilepsy. As yet, levetiracetam does not have a licence for treating this type of epilepsy, but this data suggests it is useful.
With this type of audit data, it is not generally advisable to try and compare outcomes for the three audit drugs. There are a number of reasons for this, not least that by definition the group being treated becomes more ''resistant'' to treatment with time, i.e., many people in the levetiracetam group have probably already been ''resistant'' to firstly lamotrigine and secondly topiramate before they receive levetiracetam. For most of the core data (e.g. age, sex, etc.) the three groups were similar, but people were more likely to have primary generalised epilepsy in the levetiracetam group. Whilst allowing for these reservations comparison of the data on seizure efficacy and ''drop-out'' would suggest that this data is similar to others. 15, 16, 21, [26] [27] [28] [29] Some studies have reported worse outcomes, but it would appear that their cohorts had more severe epilepsies. 20, 22 This data would suggest that topiramate is more likely to stop seizures than the other two AEDs, but in the case of levetiracetam it needs to be considered that the patient cohort is likely to be the most resistant to treatment. As has been shown in other studies this efficacy does have a downside, because people are less likely to tolerate topiramate compared with the other two AEDs. 21, 22, 30 In the United Kingdom, both lamotrigine and topiramate have very wide-ranging licences for differing seizure types. This is not the case for levetiracetam. Data from this study would suggest that levetiracetam has a wide spectrum of activity, being probably as efficacious for primary generalised epilepsy (17% seizure-free) as it is for localisationrelated epilepsy (10% seizure-free) in a population previously resistant to treatment.
The cohort contained 96 exposures to an audit AED in those with learning disabilities. People with learning disabilities are usually more resistant to treatment than others 31 and this study confirmed this. Only 5% of the exposures in this group led to seizure freedom against 13% of those who did not have learning disabilities. However, very interestingly, when you group together exposures that became seizure-free and those with a greater than 50% decrease in seizures, people with learning disabilities responded in a similar way; 35% exposure responders against 33%. This latter finding deserves more investigation and further research.
Conclusion
As 13% of the people exposures led to seizure freedom and approximately one-third had a reduction of greater than 50% in their seizures in this study, the conclusion has to be that lamotrigine, levetiracetam and topiramate are useful additions to the armamentarium of AEDs in a ''general'' population with epilepsy. Approximately, one-third of the exposures in people with a learning disability also had a substantial benefit, although the rate of seizure freedom was lower.
All three AEDs are most successful at treating primary generalised epilepsy and least successful with symptomatic generalised epilepsy.
With some reservations the data suggests that topiramate is the most efficacious AED, followed by levetiracetam, but the least well tolerated. These results mean consideration of a ''general prescribing policy'' is important when using and choosing these AEDs. Is ''power'' to stop seizures more or less important than ''power'' to avoid complications? On balance, we prefer the latter in the pursuit of high-quality long-term care.
